Immune checkpoint inhibitors (ICPis), such as pembrolizumab (Keytruda®), are associated with the development of several immune-related adverse events (irAEs). Thyroid dysfunction is a common endocrine irAE associated with pembrolizumab; however, Graves' disease induced by pembrolizumab is extremely rare. Few cases of this condition have been reported in the literature. Here, we report the case of a 50-year-old patient who presented with thyrotoxicosis that was attributed to Graves' disease secondary to pembrolizumab therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998112 | PMC |
| http://dx.doi.org/10.7759/cureus.34696 | DOI Listing |
Publication Analysis
Top Keywords
graves' disease
8
rare case
4
case pembrolizumab-associated
4
pembrolizumab-associated graves'
4
disease immune
4
immune checkpoint
4
checkpoint inhibitors
4
inhibitors icpis
4
pembrolizumab
4
icpis pembrolizumab
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!